Article Text

Download PDFPDF
Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFα reduce colitis-associated colorectal carcinogenesis?
  1. L Biancone,
  2. C Petruzziello,
  3. E Calabrese,
  4. F Zorzi,
  5. P Naccarato,
  6. S Onali,
  7. F Pallone
  1. Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università “Tor Vergata”, Roma, Italy
  1. Correspondence to Dr L Biancone, Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy; biancone{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the article by Fidder et al1 reporting, in a single-centre cohort study, the frequency of severe adverse events (SAEs) in 734 infliximab- and 666 non-infliximab treated patients with inflammatory bowel disease (IBD) followed-up in the long term (median 58 and 144 months, respectively). While no differences between the two groups were detected in terms of SAEs, mortality, infection rate and malignancies, we do believe that the type of cancer observed deserves further consideration. A comparable cancer incidence was detected in the two groups, confirming previous studies.2 3 However, while in the non-infliximab-treated group 8 out of the 666 (1.2%) patients had a newly diagnosed colorectal cancer, no patients in the infliximab group had a new diagnosis of colorectal cancer (0%) during the study period. In the infliximab group, one metastatic adenocarcinoma of unknown origin was, however, detected in one …

View Full Text


  • Funding “Fondazione Umberto Di Mario”, Largo Marchiafava 1, Rome.

  • Competing interests None.

  • Provenance and peer review Not commissioned; not externally peer reviewed.